Position in GRFS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$99
New position
Shares Held
14
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#164
of 164 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in GRFS
reported options exposure · as of Jun 30, 2026CallValue
$505,512
CallShares
71,400
PutValue
$119,652
PutShares
16,900
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $213,456,876 across 14 Drug Manufacturers - General names. GRFS ranks #14 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMGN |
Amgen Inc
|
240,318 | $87,023,954 | |
| 2 | PFE |
Pfizer Inc
|
2,417,136 | $58,204,634 | |
| 3 | LLY |
ELI LILLY & Co
|
28,457 | $34,132,182 | |
| 4 | GSK |
GSK plc
|
402,472 | $21,097,582 | |
| 5 | NVO |
Novo Nordisk A S
|
194,159 | $9,307,982 | |
| 6 | SNY |
Sanofi
|
33,051 | $1,409,955 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
18,084 | $1,042,000 | |
| 8 | JNJ |
Johnson & Johnson
|
1,394 | $354,034 |
All Filings in GRFS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $119,652 | 16,900 | Put | Sole | 2026-08-03 | |
| 2026-06-30 | $99 | 14 | Shares | Sole | 2026-08-03 | |
| 2026-06-30 | $505,512 | 71,400 | Call | Sole | 2026-08-03 | |
| No filing history on record for this holder in this stock. | ||||||